ClinicalTrialExchange
  • Home
  • For Patients
  • For Professionals
  • About
  • Contact

Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Antithrombin III Deficiency

  • Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass
  • Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery
  • Antithrombin III in Infectious Disease Caused by COVID-19
  • Response of Continuous Recombinant Antithrombin Infusion in Postcardiotomy ECMO Patients
  • Atenativ Effect on Uterine Blood Flow and Preeclampsia
  • Anti-thrombin III (ATIII) vs Placebo in Children (<7mo) Undergoing Open Congenital Cardiac Surgery
  • Response of Recombinant Antithrombin in Heparin Resistant Patients Undergoing Cardiac Surgery
  • A Study of KW-3357 in Congenital Antithrombin Deficiency
  • Use of Antithrombin in Cardiac Surgery With Cardiopulmonary Bypass
  • Safety, Pharmacokinetics and Efficacy of an AT-III Concentrate.
© Copyright 2002-2025 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies

Clinical Trials data from clinicaltrials.gov

Powered by DrugPatentWatch.

  • About
  • Contact
  • Follow ClinicalTrialsExchange:

      ClinicalTrialsExchange Linkedin Group